Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Wiegman

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
The Lancet. Diabetes & Endocrinology|January 30, 2026
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trialAlbert Wiegman, Amy L Peterson, Eric Bruckert, et al.
Journal of Clinical Lipidology|October 9, 2022
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemiaDaniel Gaudet, Andrea Ruzza, Ian Bridges, et al.
Journal of the American College of Cardiology|August 26, 2017
Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic MutationsEvan A Stein, Eldad J Dann, Albert Wiegman, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|December 21, 2018
Regional assessment of carotid artery pulse wave velocity using compressed sensing accelerated high temporal resolution 2D CINE phase contrast cardiovascular magnetic resonanceEva S Peper, Gustav J Strijkers, Katja Gazzola, et al.
European Journal of Preventive Cardiology|October 19, 2023
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatmentRaul D Santos, Andrea Ruzza, Bei Wang, et al.
Atherosclerosis|December 7, 2019
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesUma Ramaswami, Marta Futema, Martin P Bogsrud, et al.
European Journal of Preventive Cardiology|September 5, 2022
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendationsSamuel S Gidding, Albert Wiegman, Urh Groselj, et al.
Atherosclerosis|January 8, 2026
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemiaRobert S Rosenson, Eliot A Brinton, Daniel Gaudet, et al.
Atherosclerosis|May 18, 2021
Marked plaque regression in homozygous familial hypercholesterolemiaLaurens F Reeskamp, Nick S Nurmohamed, Michiel J Bom, et al.
European Heart Journal|March 4, 2014
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcomeBarbara Sjouke, D Meeike Kusters, Iris Kindt, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
The Lancet. Diabetes & Endocrinology|January 30, 2026
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trialAlbert Wiegman, Amy L Peterson, Eric Bruckert, et al.
Journal of Clinical Lipidology|October 9, 2022
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemiaDaniel Gaudet, Andrea Ruzza, Ian Bridges, et al.
Journal of the American College of Cardiology|August 26, 2017
Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic MutationsEvan A Stein, Eldad J Dann, Albert Wiegman, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|December 21, 2018
Regional assessment of carotid artery pulse wave velocity using compressed sensing accelerated high temporal resolution 2D CINE phase contrast cardiovascular magnetic resonanceEva S Peper, Gustav J Strijkers, Katja Gazzola, et al.
European Journal of Preventive Cardiology|October 19, 2023
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatmentRaul D Santos, Andrea Ruzza, Bei Wang, et al.
Atherosclerosis|December 7, 2019
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesUma Ramaswami, Marta Futema, Martin P Bogsrud, et al.
European Journal of Preventive Cardiology|September 5, 2022
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendationsSamuel S Gidding, Albert Wiegman, Urh Groselj, et al.
Atherosclerosis|January 8, 2026
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemiaRobert S Rosenson, Eliot A Brinton, Daniel Gaudet, et al.
Atherosclerosis|May 18, 2021
Marked plaque regression in homozygous familial hypercholesterolemiaLaurens F Reeskamp, Nick S Nurmohamed, Michiel J Bom, et al.
European Heart Journal|March 4, 2014
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcomeBarbara Sjouke, D Meeike Kusters, Iris Kindt, et al.
Pageof 13